Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.65 |
| ▸ | DGKA | P23743 | 1/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.42 |
| ▸ | PAM | P19021 | 2/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | THRA | P10827 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14239733 | 0.93 | DNM1 (0.56) | DNM1DGKATSHRMAPTALDH1A1 | |
| SCHEMBL21027067 | 0.92 | DNM1 (0.55) | DNM1DGKAPRSS1PRSS2PRSS3 | |
| SCHEMBL17528637 | 0.92 | DNM1 (0.55) | DNM1DGKAPRSS1PRSS2PRSS3 | |
| SCHEMBL22063092 | 0.91 | DNM1 (0.54) | DNM1DGKAPRSS1PRSS2PRSS3 | |
| SCHEMBL17586414 | 0.91 | DNM1 (0.53) | DNM1DGKATSHRMAPTALDH1A1 | |
| SCHEMBL21467209 | 0.91 | DNM1 (0.53) | DNM1DGKATSHRMAPTALDH1A1 | |
| SCHEMBL17581848 | 0.90 | DNM1 (0.53) | DNM1TSHRMAPTLMNAALDH1A1 | |
| SCHEMBL21336568 | 0.90 | DNM1 (0.53) | DNM1TSHRMAPTLMNAALDH1A1 | |
| SCHEMBL16133359 | 0.89 | DNM1 (0.53) | DNM1DGKAPRSS1PRSS2PRSS3 | |
| SCHEMBL18469356 | 0.88 | DNM1 (0.53) | DNM1DGKATSHRMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617754-B2 | Process for synthesizing lipids | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-05-05 | — | — | US | disclosed |
| EP-4171579-B1 | PROCESS FOR SYNTHESIZING LIPIDS | BRISTOL MYERS SQUIBB CO (US) | 2026-02-25 | — | — | EP | disclosed |
| US-12440445-B2 | Fusogenic compounds for delivery of biologically active molecules | NITTO DENKO CORPORATION (JP) | 2025-10-14 | — | — | US | disclosed |
| US-20230250056-A1 | PROCESS FOR SYNTHESIZING LIPIDS | BRISTOL-MYERS SQUIBB COMPANY | 2023-08-10 | — | — | US | disclosed |
| US-20230250056-A1 | PROCESS FOR SYNTHESIZING LIPIDS | BRISTOL-MYERS SQUIBB COMPANY | 2023-08-10 | — | — | US | disclosed |
| EP-4171579-A1 | PROCESS FOR SYNTHESIZING LIPIDS | Bristol-Myers Squibb Company (US) | 2023-05-03 | — | — | EP | disclosed |
| US-11633365-B2 | Nucleic acid-containing lipid nanoparticle | KYOWA KIRIN CO., LTD. (JP) | 2023-04-25 | — | — | US | disclosed |
| US-20220233445-A1 | FUSOGENIC COMPOUNDS FOR DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES | NITTO DENKO CORPORATION (JP) | 2022-07-28 | — | — | US | disclosed |
| EP-2858974-B9 | LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS | NITTO DENKO CORP (JP) | 2022-07-20 | — | — | EP | disclosed |
| WO-2021262746-A1 | PROCESS FOR SYNTHESIZING LIPIDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-12-30 | — | — | WO | disclosed |
| WO-2012170952-A9 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY | NITTO DENKO CORPORATION (JP) | 2013-02-21 | — | — | WO | disclosed |
| WO-2012170952-A9 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY | NITTO DENKO CORPORATION (JP) | 2013-02-21 | — | — | WO | disclosed |
| US-20130022665-A1 | CATIONIC LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS | NITTO DENKO CORPORATION (JP) | 2013-01-24 | — | — | US | disclosed |
| US-20130022665-A1 | CATIONIC LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS | NITTO DENKO CORPORATION (JP) | 2013-01-24 | — | — | US | disclosed |
| US-20130022665-A1 | CATIONIC LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS | NITTO DENKO CORPORATION (JP) | 2013-01-24 | — | — | US | disclosed |
| US-20130017249-A1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY | NITTO DENKO CORPORATION (JP) | 2013-01-17 | — | — | US | disclosed |
| US-20130017249-A1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY | NITTO DENKO CORPORATION (JP) | 2013-01-17 | — | — | US | disclosed |
| WO-2012170952-A2 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY | NITTO DENKO CORPORATION (JP) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012170957-A2 | RETINOID-LIPOSOMES FOR ENHANCING MODULATION OF HSP47 EXPRESSION | NITTO DENKO CORPORATION (JP) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012170952-A2 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING SIRNA ACTIVITY | NITTO DENKO CORPORATION (JP) | 2012-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250056-A1 | PROCESS FOR SYNTHESIZING LIPIDS | PLIN1, SREBF1, SREBF2 | DNM1 1086/4885DGKA 119/4885PRSS1 1007/4885 |
| US-20130022665-A1 | CATIONIC LIPIDS FOR THERAPEUTIC AGENT DELIVERY FORMULATIONS | SGMS1, SGMS2, S1PR3 | DNM1 714/4885DGKA 2435/4885PRSS1 1682/4885 |
| US-11633365-B2 | Nucleic acid-containing lipid nanoparticle | LIPA, LIPC, PNLIP | DNM1 3155/4885DGKA 66/4885PRSS1 1163/4885 |
| US-20130017249-A1 | COMPOUNDS FOR TARGETING DRUG DELIVERY AND ENHANCING siRNA ACTIVITY | LDLR, RARG, FABP4 | DNM1 1133/4885DGKA 195/4885PRSS1 3232/4885 |
| US-12617754-B2 | Process for synthesizing lipids | LIPC, PHOSPHO1, SGMS1 | DNM1 273/4885DGKA 92/4885PRSS1 2805/4885 |
| US-20220233445-A1 | FUSOGENIC COMPOUNDS FOR DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES | FUS, NSF, FABP7 | DNM1 285/4885DGKA 1812/4885PRSS1 1028/4885 |
| US-12440445-B2 | Fusogenic compounds for delivery of biologically active molecules | FUS, NSF, FABP7 | DNM1 285/4885DGKA 1812/4885PRSS1 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.